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SUMMARY.-Washed lymphocytes from immunized rats showed no reaction
against mouse plasmacytoma 5563 in vivo or in vitro.
Cell-free lymph from immunized rats was shown to be cytotoxic to the
tumour cells in vitro. This effect we have shown to be solely in the 19s fraction
after Sephadex G-200 separation.
This 19s fraction conferred partial protection to tumour bearing mice when
given shortly after transplantation, but had negligible effect against late well
established tumour.
THE occurrence of specific antigens on the surface of tumour cells, which are
different from that of the host normal histocompatibility antigens, is well estab-
lished (Alexander and Fairley, 1967). Cellular or antibody mediated immunity
or both against such antigens has been demonstrated. Why these are largely
ineffective is not yet fully understood, and attempts at passive transfer of the
immunity are being considered.
Delorme and Alexander (1964), using chemically induced fibrosarcoma in rats,
were able to show temporary regressions of tumour growth by treatment with
syngeneic lymphocytes, or sheep lymph node cells (Alexander et al., 1966), taken
from immunized animals, but complete regressions were rarely achieved.
In further experiments (Alexander et al., 1967), showed that the same effect
couldbeobtained using RNA extracted from these lymphocytes, andtheysuggested
that the effect results from augmenting an already existing immune response,
and this is related to the life span of the messenger RNA. Southam and Dizon
(1969), using immunocytes derived from immune rats were successful in treating
tumours formed in rats after transplanting human tissue culture cell line J-111
into newborn allogeneic rats when the treatment was initiated within one week
after transplantation.
Circulating antibodies to chemically orphysically inducedsarcomaorcarcinoma
were not detected, but antibodies cytotoxic to the tumour cells in vitro are usually
found with leukaemias, and complement was found to be necessary for the
reaction (Klein and Klein, 1964; Old and Boyse, 1964).
In vivo, it is known that the presence of antibodies might have an adverse
effect on tumour rejection, in other words, it can result in immunological enhance-
ment (Irvine, Eustace and Fahey, 1967). It was thought that such antibodies
were coating the cell surface antigens and thus preventing the destructive effect
of the lymphocytes; however, the mechanism of the enhancement is certainly
more complex (Hellstrom andMoller, 1965).0. FAKHRI AND J. R. HOBBS
Gorer and Amos (1956) using specifically immune sera of allogeneic origin were
able to protect C57/BL mice against subsequent challenge withisogeneicleukaemnia.
Retardation of growth was only obtained when the sera were administered not
later than 2 days after the transplantation of the tumour cells.
Using plasmacytoma MP5563 in C3H mice, the growth characteristics and
protein production of which have been previously studied (Fakhri, 1970; Fakhri
and Hobbs, 1970), we attempted to use washed rat immune lymphocytes to
challenge the tumour in vivo. To these the tumour did not show any trace of
response. We then studied in vitro the effect on the tumour of whole thoracic
duct lymph to see if any cofactor is necessary for the reaction ofthe lymphocytes.
This was not shown to be the case, but we found an antibody in the 19s fraction
which is highly cytotoxic to the tumour cells in vitro.
In vivo preliminary results suggest that when the rat 19s fraction is giveni
shortly after transplantation it is possible to prolong the survival ofthe inoculated
mice. However, they are still eventually dying from their tumour, and this is
under further investigations.
MATERIALS AND METHODS
Tumour. Plasmacytoma 5563 in ascitic form used in previous work (Fakkhri
1970; Fakhri and Hobbs 1970).
Animals. C3H mice of both sexes (8-12 weeks old), and albino rats (mlale
6 months old) were used.
Immunizationprocedure
Ascitic fluid from tumour bearing mice was freshly collected. The fluid as-cis
then centrifuged and the supernatant was discarded. The tumour cells were thenl
freed from any red cells by the method ofJanowsky et al. (1964), and the residual
tumour cells were washed with normal saline. Then 30 X 106 live tumour cells
suspended in saline, divided in equal doses, were given to each rat bv subcutaneouis
injections into each of the hind legs together with one intraperitoneal injectioin.
One week later similar booster doses were given.
Cannulation procedure
Using the Gowan's technique, the thoracic ducts of the immunized rats were
cannulated 2-3 days after giving the booster dose, and this was maintained for 2
days. It was found a cannula made of two parts was most convenient:
(1) The head part was made from a piece of nylon intravenous cannula O.D.
1*02 mm. (Portex Ltd.), which was bent over very gentle flame to a hook-like
shape. Its tip was sharpened by cutting it obliquely to facilitate penetratioln of
the duct directly, without previous puncture which might cause the duct to
collapse.
(2) The head was attached to transluscent vinyl tubing (Portex Ltd) which wi-as
very soft and absorbed any shock to the external part ofthe cannula which might
be conducted to the head, dislodging it from the duct (Fig. 1).
The animals were given 0*1 mg. Vit. K. before cannulation and fed 500 glucose
in normal saline when lymphocytes alone were required, or were on water for
experiments in which we used whole lymph or cell-free lymph fluid. The lymph
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0. D. 1.02 mm. ( PORTEX LTD )
VINYL TUBING ( PORTEX
FiG. 1.-A two piece cannula suitable for thoracic duct cannulation of the rat.
was collected into 100 ml. siliconized sterile glass flasks, into which 1 ml. ofheparin
solution (250 units/ml.) was placed, the flask being agitated every few minutes.
Immunotherapy procedures
Lymph was collected from previously immunized rats every 12 hours from 3-5
days after boosting. The cell content was counted and cell viability was deter-
mined by the dye exclusion technique. Where washedlymphocytes were required
these were obtained by centrifuging gently for 5 minutes; the supernatant was
discarded and the cells were then washed in TC199 and resuspended in the same
medium to contain the required number oflymphocytes per therapy dose (in not
more than 1 ml. of medium). Although these rat lymphocytes seemed perfectly
viable, we were unsuccessful in attempts to grow them in vitro in tissue culture,
and thus were never able to test them for lymphocyte transformation against the
mouse cells.
In preliminary experiments, fresh washed lymphocytes were given either
intravenously or intraperitoneally in one dose (either 25, 50 or 100 x 106) into
mice which had been previously transplanted with 100-250,000 tumour cells.
Treatment given at intervals from 0-5 days after transplantation was tried,
without success. When it was shown that whole rat lymph could be effective the
following experiments were made, initially with a short period of in vitro mixing
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(to ensure complete contact of all components) before inoculation, and finallY
with in vivo therapy ofthe tumour.
The In Vitro Effect of Rat Thoracic Duct Lymph
Fresh tumour cells were always used; these were gently centrifuged, the
supernatant was discarded and the cells were resuspended in saline to contain
5 x 106 cells per ml.
Incubation was done in sterile siliconized glass universals at room temperature.
The lymph used was always fresh from within 4-6 hours ofcollection.
Experiment 1 The effect of whole lymphfluid
In this experiment 106 tumour cells in 0*2 ml. saline were incubated for 10 hours
with 0.8 ml. whole lymph which contained 40 x 106 lymphocytes per ml. freshly
collected from an immunized rat. Similarly tumour cells were incubated with
whole lymph from an unimmunized rat. At the same time the same number of
tumour cells were incubated with 0.8 ml. normal saline in a similar bottle as
control. Then 0.1 ml. of the mixture from each bottle, containing 105 tumour
cells. was transplanted into each of groups of 5 mice.
Experiment 2 The effect of washed lymphocytes or cell-free lymph
In this experiment 106 tumour cells in 0-2 ml. saline were transferred into each
of 4 bottles (A, B, C, D) to which the following additions were made: (A) 0-8 ml.
saline; (B) 0-8 ml. of whole lymph fluid containing 250 x 106 lymphocytes from
an immunized rat; (C) 0 8 ml. of lymphocyte-free lymph from an immunized rat;
(D) 250 x 106 lymphocytes from an immunized rat: they were washed and re-
suspended in 0-8 ml. normal saline. After 10 hours incubation, 0 1 ml. from each
bottle was transplanted into each of groups of 5 mice.
Experimnent 3- Determination of the effective fraction after separation through
Sephadex G200
Twelve ml. ofcell-free lymph from an immunized rat was applied to a Sephadex
G200 column. The three main peaks were collected and concentrated by vacuum
ultrafiltration down to the original volume of the lymph. The fractions were
then dialysed against phosphate buffered saline for 48 hours at 40 C. and finally
sterilized by millipore filtration. Into 5 bottles (E, F, G, H, 1) 106 tumour celis
in 0-2 ml. saline were transferred and the following additions were made: (E)
0.8 ml. normal saline; (F) 0*8 ml. fraction 19s; (GI) 0*8 ml. fraction 7s; (H) 0.8 ml.
fraction 4s; (I) 0 8 ml. whole lymph.
Subsequently bottle G2 was set up using 0*8 ml. of fraction 7s which had been
recycled through Sephadex G200 to free it from the originally contaminating tail
of the 19s fraction.
Each bottle was then incubated for 10 hours at room temperature, and there-
after 0.1 ml. (105 tumour cells) was inoculated, using groups of 5 mice for each
bottle.
The In Vivo Effect of 19s Fractionfrom Immune Rat Lymph
Experiment 4
Four groups (J, K, L, M) of 5 mice were inoculated with 105 tumour cells.
(J) was left as the control; (K) received 0*5 ml. of lOs fraction intraperitoneally 30
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minutes after inoculation; (L) received 0.5 ml. doses of 19s fraction at 30 minutes,
1 day, 2 days and 3 days after inoculation; (M) was given 0.5 ml. of 19s fraction
at 6 days, 7 days and 8 days after inoculation:
Controls
Throughout the above experiments the following controls were used:
(i) Tumour cells in saline without any other addition were inoculated to
check the viability and take ofthe tumour being used.
(ii) Wholethoracicduct lymphorwashedlymphocytes from unimmunized litter
mates ofthe immunized rats were used to screen for any natural immune reaction.
(iii) Mice not inoculated with tumour were given the lymph (or its products)
from immunized rats to check for any obvious side-reactions against the normal
tissues of the mouse.
Mode ofaction of 19sfraction
The in vitro studies (exp. 3, F) were repeated, also using 19s fraction heated to
560 C. for half an hour to see if complement (also contained in the front peak
from Sephadex G200) was necessary.
Trypan blue exclusion studies were made of both MP 5563 cells and normal
C3H mouse cells (from peritoneal washings or from dextranized blood) before and
after incubation with active 19s fraction.
RESULTS
Using the survival as a criterion, the preliminary in vivo therapy using washed
lymphocytes (fromimmunizedrats) indifferent doses andatdifferenttimeintervals
after transplantation did not cause any marked difference whethertheywere given
intravenously or intraperitoneally. Dye exclusion studies had shown that rat
lymphocytes were still 95% viable after washing.
TABLE L.-Results ofExperiment 1; In Vitro Effect ofImmune Rat Thoracic
Duct Lymph Against MP 5563
Thoracic duct lymph from
Incubation with . Saline control . Normal rat Immunized rat
Survival . All dead within . All dead within All alive at 6
14 days 14 days months
TABLE II.-Results ofExperiment 2; the In Vitro Effect ofImmune Cell-free
Lymph Against MP 5563
Immune rat lymph
Incubation with . Saline control . Whole lymph Cell free lymph Washed viable
lymphocytes
250 per tumour
cell
A B C D
Survival . All dead within . All alive at 5 All alive at 5 All dead within
14 days months months 14 days
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TABLE III.-Results of Experiment 3; the Fraction of Cell-free Lymph Effective
In Vitro Against MP 5563
Sephadex G200 fraction of immune rat lymph
A
Incubated . Saline . 19s First 7s Recycled 7s 4s Whole lymph
with control (+ trail 19s) (no 19s)
E F Gl G2 H I
Survival . All dead . All alive 3/5 mice All dead All dead All alive at
within at 4 developed within within 4 months
14 days months the tumour 14 days 14 days
and died
within 30
days. 2/5
alive at
4 months
TABLE IV.-Results of Experiment 4; the In Vivo Effect of Immune 19s Fraction
at Various Intervals After Inoculation of MP 5563
Control no treatment . 0*5 ml. at 30 min . 0*5 ml. at 30 min. . 0 5 ml. on days 6,
only and on days 1, 2 7 and 8
and 3
J K L M
All dead within 14 days . All dead, average . All dead, average . All dead within
survival 26 days survival 26 days 16 days
The results of experiments 1-4 are shown in Table I-IV. Throughout, the
controls revealed (i) that 105 of the tumour MP 5563 cells were regularly lethal
within 14 days (ii) that rat lymph from unimmunized litter mates was without
effect and (iii) that in the doses used the immune rat lymph showed no obvious
side effects on normal C3H mice.
From the above results it can be concluded that the effect ofimmune rat lymph
is confined solely to the 19s cell-free fraction. With the guaranteed contact of
prior in vitro incubation this 19s fraction can completely eliminate the successful
take of MP 5563. In vivo its effect is as yet only to prolong survival, and even
this effect seems largely confined to the first dose given 30 minutes after the inocu-
lation of MP 5563. Doses thereafter have only a minimal effect.
The 19s fraction was ineffective after heat inactivation, so presumably requires
complement for its action. The trypan blue exclusion studies revealed almost
total killing of the MP 5563 cells after incubation in vitro, but also showed 85%
killing ofthe normal C3H white cells from either peritoneal washings or peripheral
blood.
DISCUSSION
Lymphocytes from immunized rats had no effect on the mouse tumour (in
vivo or in vitro), in spite ofthe large doses given (up to 500 lymphocytes per tumour
cell) and although they had been collected at the time when the lymph was
expected to contain a high proportion of immunoblasts (8-12%) (Delorme et al.,
1969).
The purpose of injecting the lymphocytes between day 0 and day 5 after
transplantation was to attack the tumour before it became established and to show
any synergism between the injected rat lymphocytes and any immune reaction
of the mouse, such as that found by Alexander et al. (1967). The intravenous
or intraperitoneal injection of the lymphocytes did not show any effect. The
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differences in the nature of the two experimental tumours might account for the
differences in the effectiveness of the rat lymphocytes. The present tumour had
originally arisen spontaneously in mice, whereas that of Alexander's team had
been chemically induced.
The ineffectiveness ofthe washed rat lymphocytes to reject the tumour led us
tolookforany cofactorwhichmightbenecessaryforthe action ofthelymphocytes.
The cytotoxic effect found was shown later to be mediated only by the 19s
fraction which presumably contained IgM antibodies. This reaction was inacti-
vated by heating to 560 C. and presumably involved the fixation of complement.
The partial cytotoxic effect of the first 7s fraction was shown to be due to the
presence of some 19s fraction in it, tailing from the first peak. This effect was
abolished when the 7s fraction was recycled through the column and freed from
any contamination from the 19s fraction.
The possible application of the 19s fraction in therapy of the plasmacytoma
was considered in experiment 4. The results would depend upon whether this
antibody was directed specifically against the tumour or against normal tissue
histocompatibility antigens aswell. Itdoes seemfromthefinaltrypanbluestudies
that the 19s fraction has both activities. It may not be all used up by the normal
tissues of the mouse, although this does diminish its effectiveness. While as yet
the mice are not obviously harmed by the doses given, preliminaryresults indicate
the normal cells of the mouse are so vulnerable that larger doses of unadsorbed
19sfractionwouldbeharmful. It also seemsthatthefirstdoseistheonlyonethat
is really effective and that subsequent doses do not prolong survival further (see
Table IV). This might suggest that the mouse forms an antibody against this rat
19s fraction which prevents its further effectiveness. The effect of the first dose
on an established tumour in vivo was not of curative value, although the tumour
could be killed in vitro. The in vivo dose may have been too small to be effective
on a well grown tumour or alternatively the late tumour might have become
protected in vivo by an enhancing antibody, etc. Adsorption studies will be
undertaken to try and produce a tumour-specific antibody, so that a larger dose
may be given and it is hoped to also encourage a cellular immune response from
the rat by modifying the tumour antigen.
This investigation has been supported by a grant from the British Empire
Cancer Campaign. We are most grateful to Dr. E. J. Delorme for his helpful
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